Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
about
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolismNovel agents for advanced pancreatic cancerMEK and the inhibitors: from bench to bedside.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical modelsTargeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.Molecular targeted approaches for treatment of pancreatic cancer.Novel mitogen-activated protein kinase kinase inhibitors.MEK inhibitors: a patent review 2008 - 2010.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Prospects for MEK inhibitors for treating cancer.The biology and clinical development of MEK inhibitors for cancer.Imaging Mass Cytometry.Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
P2860
Q24608066-580C2A74-CDCF-49B2-9D36-2EA8E06187DAQ26787087-3B976927-238F-4464-BAA6-0AF53A1FAE4BQ34036341-9C5D1333-7C45-4C06-94A0-0AC524D0B386Q34307356-646B5C00-BE6D-4339-B974-5AFB90E6E590Q34406302-E504C1CC-DED4-4736-98A9-0C48D8ACA915Q35018805-31AD303B-CACB-4745-B97B-C59504625469Q35537413-893471C6-5A3D-44FB-A145-4690E4831D62Q36174910-9BF8B7B8-AD10-4330-9714-68CB14596CC6Q37828536-0916A378-D85C-48A0-BE66-BD00C1C340D9Q37872791-5C2FF0CE-164D-4C74-AC6D-14EF2F48FCA8Q38053855-775BAB1A-3DEF-4106-B6D0-B8DF66BDE85FQ38193520-64B1AF6F-32D1-4445-AFD6-507A56095E63Q38270129-88024545-5C37-4E4F-BEC4-9E39D1A418ADQ39119302-1DBCA95C-4130-435A-A7BA-58CB1DA5D085Q47098844-48E3D70E-7D4E-452B-AED1-DC84950EEA9F
P2860
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@ast
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@en
type
label
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@ast
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@en
prefLabel
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@ast
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@en
P2093
P2860
P356
P1433
P1476
Antitumour activity of a poten ...... pancreatic cancer xenografts.
@en
P2093
Jeffrey N Miner
Mark S Chapman
Qing Chang
P2860
P2888
P356
10.1186/1471-2407-10-515
P407
P50
P577
2010-09-28T00:00:00Z
P5875
P6179
1018940730